Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adaptive RadioTherapy for OroPharynx Cancer
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Summary
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.
Official title: Adaptive RadioTherapy for Locally Advanced OroPharynx Cancer (ART-OPC) A Phase II Randomized Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2021-07-30
Completion Date
2026-12
Last Updated
2023-12-12
Healthy Volunteers
No
Interventions
Standard radiotherapy +/- chemotherapy
No radiotherapy adaptation unless major dosimetric deviation
Experimental radiotherapy +/- chemotherapy
Systemic MRI-based radiotherapy adaptation mid-treatment
Locations (2)
Austin Health
Melbourne, Australia
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada